Biocon Ltd.

NSE: BIOCON | BSE: 532523 | ISIN: INE376G01013 | Industry: Biotechnology
| Mid-range Performer
356.9500 -2.50 (-0.70%)
NSE Aug 21, 2025 10:33 AM
Volume: 375.1K
 

logo
Biocon Ltd.
27 Aug 2016
356.95
-0.70%
Rudra Shares and Stock Brokers Ltd
Biocon is one of the largest insulin's producer in Asia and its rh-Insulin today, has marketing approvals in 60 countries & over 20 countries for Insulin Glargine. As on 25th Aug. 2016, European Medicines Agency (EMA) has accepted to review Mylan and Biocon's application for a biosimilar called Trastuzumab, used for certain breast and gastric cancers. Marketing approval for the drug is likely to come in next 12-18 months having an addressable market close to USD 7 billion, which opens up a huge opportunity for Biocon and Mylan both. This is the second biosimilar submission developed by partnership that has been accepted for review in Europe. Last month, Mylan's...
Axis Direct increased Buy price target of Biocon Ltd. to 380.0 on 11 Aug, 2025.
More from Biocon Ltd.
Recommended